Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.

Sho M, Akahori T, Tanaka T, Kinoshita S, Tamamoto T, Nomi T, Yamato I, Hokuto D, Yasuda S, Kawaguchi C, Nishiofuku H, Marugami N, Enomonoto Y, Kasai T, Hasegawa M, Kichikawa K, Nakajima Y.

J Hepatobiliary Pancreat Sci. 2013 Feb;20(2):197-205. doi: 10.1007/s00534-012-0532-8.

PMID:
22766692
2.

Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.

Sho M, Akahori T, Tanaka T, Kinoshita S, Nagai M, Nishiwada S, Tamamoto T, Nishiofuku H, Ohbayashi C, Hasegawa M, Kichikawa K, Nakajima Y.

Langenbecks Arch Surg. 2015 May;400(4):477-85. doi: 10.1007/s00423-015-1304-0. Epub 2015 May 1.

PMID:
25929828
3.

A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.

O╩╝Reilly EM, Perelshteyn A, Jarnagin WR, Schattner M, Gerdes H, Capanu M, Tang LH, LaValle J, Winston C, DeMatteo RP, D╩╝Angelica M, Kurtz RC, Abou-Alfa GK, Klimstra DS, Lowery MA, Brennan MF, Coit DG, Reidy DL, Kingham TP, Allen PJ.

Ann Surg. 2014 Jul;260(1):142-8. doi: 10.1097/SLA.0000000000000251.

4.

Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer.

Kim MS, Lim JS, Hyung WJ, Lee YC, Rha SY, Keum KC, Koom WS.

World J Gastroenterol. 2015 Mar 7;21(9):2711-8. doi: 10.3748/wjg.v21.i9.2711.

5.

Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.

Homma Y, Taniguchi K, Murakami T, Nakagawa K, Nakazawa M, Matsuyama R, Mori R, Takeda K, Ueda M, Ichikawa Y, Tanaka K, Endo I.

Ann Surg Oncol. 2014 Feb;21(2):670-6. doi: 10.1245/s10434-013-3390-y. Epub 2013 Dec 6.

PMID:
24310792
6.

Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.

Satoi S, Toyokawa H, Yanagimoto H, Yamamoto T, Kamata M, Ohe C, Sakaida N, Uemura Y, Kitade H, Tanigawa N, Inoue K, Matsui Y, Kwon AH.

J Gastrointest Surg. 2012 Apr;16(4):784-92. doi: 10.1007/s11605-011-1795-0. Epub 2011 Dec 9.

PMID:
22160780
7.

Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.

Kubota K, Sato T, Watanabe S, Hosono K, Kobayashi N, Mori R, Taniguchi K, Matsuyama R, Endo I, Nakajima A.

Dig Endosc. 2014 Jan;26(1):77-86. doi: 10.1111/den.12049. Epub 2013 Mar 31.

PMID:
23551230
8.

[The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].

Sano T, Takano K, Chiba N, Tomita K, Ozawa Y, Hikita K, Shimazu M, Kawachi S.

Gan To Kagaku Ryoho. 2015 Nov;42(12):1488-90. Japanese.

PMID:
26805072
9.

Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.

Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, Yano M, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K.

Ann Surg. 2009 Jul;250(1):88-95. doi: 10.1097/SLA.0b013e3181ad65cc.

PMID:
19561477
10.

Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy.

Akahori T, Sho M, Kinoshita S, Nagai M, Nishiwada S, Tanaka T, Tamamoto T, Ohbayashi C, Hasegawa M, Kichikawa K, Nakajima Y.

World J Surg. 2015 Dec;39(12):2975-82. doi: 10.1007/s00268-015-3205-3.

PMID:
26296840
11.

Inverse Probability of Treatment Weighting Analysis of Upfront Surgery Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Pancreatic Adenocarcinoma with Arterial Abutment.

Fujii T, Yamada S, Murotani K, Kanda M, Sugimoto H, Nakao A, Kodera Y.

Medicine (Baltimore). 2015 Sep;94(39):e1647. doi: 10.1097/MD.0000000000001647.

12.

Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.

Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG, Meyer T, Merkel S, Fietkau R, Hohenberger W.

Strahlenther Onkol. 2015 Jan;191(1):7-16. doi: 10.1007/s00066-014-0737-7. Epub 2014 Sep 25.

13.

[Neoadjuvant Chemotherapy Using S-1 for Pancreatic Cancer - Mid-Term Results].

Homma Y, Honda G, Sakamoto K, Kurata M, Honjo M, Hirata Y, Shinya S.

Gan To Kagaku Ryoho. 2016 Oct;43(10):1166-1170. Japanese.

PMID:
27760934
14.

Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.

Taira K, Boku N, Fukutomi A, Onozawa Y, Hironaka S, Yoshino T, Yasui H, Yamazaki K, Taku K, Hashimoto T, Nishimura T.

J Gastroenterol. 2008;43(11):875-80. doi: 10.1007/s00535-008-2236-z. Epub 2008 Nov 18.

PMID:
19012041
15.

Portal vein stenosis after pancreatectomy following neoadjuvant chemoradiation therapy for pancreatic cancer.

Tsuruga Y, Kamachi H, Wakayama K, Kakisaka T, Yokoo H, Kamiyama T, Taketomi A.

World J Gastroenterol. 2013 Apr 28;19(16):2569-73. doi: 10.3748/wjg.v19.i16.2569.

16.

Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB.

Ann Surg Oncol. 2001 Mar;8(2):123-32.

PMID:
11258776
17.

Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.

Stokes JB, Nolan NJ, Stelow EB, Walters DM, Weiss GR, de Lange EE, Rich TA, Adams RB, Bauer TW.

Ann Surg Oncol. 2011 Mar;18(3):619-27. doi: 10.1245/s10434-010-1456-7. Epub 2011 Jan 7.

PMID:
21213060
18.

Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy.

Chao YJ, Sy ED, Hsu HP, Shan YS.

BMC Surg. 2014 Sep 25;14:72. doi: 10.1186/1471-2482-14-72.

19.

Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.

Allendorf JD, Lauerman M, Bill A, DiGiorgi M, Goetz N, Vakiani E, Remotti H, Schrope B, Sherman W, Hall M, Fine RL, Chabot JA.

J Gastrointest Surg. 2008 Jan;12(1):91-100. Epub 2007 Sep 5.

PMID:
17786524
20.

Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.

Satoi S, Yanagimoto H, Toyokawa H, Takahashi K, Matsui Y, Kitade H, Mergental H, Tanigawa N, Takai S, Kwon AH.

Pancreas. 2009 Apr;38(3):282-8. doi: 10.1097/MPA.0b013e31819438c3.

PMID:
19142173

Supplemental Content

Support Center